"&#xa0;\n&#xa0;\nWritten evidence from the British Society for Rheumatology (LTC 88)The British Society for Rheumatology (BSR)\n exists to promote excellence in the treatment of people with arthritis and musculoskeletal conditions and to support those delivering it.\n \nAs a professional association representing those \nspecialising\n in \nrheumatic and \nmusculoskeletal conditions, BSR aims to improve standards of care in rheumatology. \nThe BSR welcomes the opportunity to contribute to thi\ns timely\n, necessary\n and important inquiry.\n&#xa0;\nKey Points:\n&#xa0;\nThe impact of rheumatic disease1.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nRheumatology is a multidisciplinary branch of medicine that deals with the investigation, diagnosis and management of patients with rheumatic diseases and other musculoskeletal conditions. This incorporates over 200 disorders affecting joints, muscles and soft tissues, including autoimmune disorders and spinal pain. A significant number of rheumatic conditions also affect other organ systems\n. \n&#xa0;\n2.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nRheumatic diseases are often under-prioritised, in part due to low levels of \npublic \nawareness about\n what rheumatology is\n.\n \nA recent survey\n conducted by the \nAmerican\n C\nollege of Rheumatology indicated\n \nthat the word ‘Rheumatology’ is for the majority of public participants not known\n. For others it was commonly associated with\n foot doctors/podiatry\n, or viewed solely as an issue relating to old age\n.\n In the UK, the low profile of rheumatology is reflected in the fact that it is only mentioned once in the Department of Health\n’s Long Term Conditions C\nompendium\n.\n&#xa0;\n3.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nDespite low awareness, musculoskeletal conditions are the the single biggest cause of disability, accounting for 31% of the total \nUK\n burden\n. I\nn contrast \nto \nencouraging \nimprovement\n trends for \npremature mortality\n, the \nUK\n trend for \nchronic \ndisability burden is getting worse. \nI\nn a rece\nnt international comparison of \ndisability adjusted life years in \ndeveloped countries with similar economies, the UK \nranks a mere 16\n out of 19 for \nosteoarthritis, and 15 out of 19 for low back pain\n \n. C\noupled w\nith the \nknown health service \nchallenge\n of an a\ngeing population\n, it is therefore vital to reverse the trend of avoidable disability through the quality improvement of rheumatology services\n.\n&#xa0;\n4.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nA key issue to address is the collection of data, which has failed to evolve over time to take account of the transformation in rheumatology treatment options. Patients with rheumatic disease \nused to \noccupy\n a great number of\n hospital \nbeds;\n however\n drug therapy now allows the provision to be largely ambulatory\n. \nCommissioners therefore have little to inform \ntheir service specifications, and\n there is insufficient\n public health epidemiology data \nto inform Joint Strategic Needs Assessments.\n \nThe fact there are over 200 conditions can\n further\n hinder understanding and therefore the BSR has created a simpler domain and pathway app\nroach. \n&#xa0;\n5.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nAlthough rheumatology services \nno longer\n \nservices are no longer mainly inpatient rehabilitation services\n involving\n hospital\n admission, the p\notential \nfor \nQuality, Innovation, Productivity and Prevention (QIPP) savings remain significant, as £680m was spent on drug therapy in England alone in 2012. S\navings come from treating people to NICE and national standards and early diagnosis and intervention, and include\n:\n6.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nBelow we outline some examples in which rheumatology services have been configured to offer the patient benefits and reduced costs outlined above.\n \nHowever service provision remains varied throughout the \nUK; the challenge is therefore to enable the delivery of consistently excellent services.\nEarly intervention and the integrated care patient pathway7.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nUnlike other services which can be wholly community-based, effective \nrheumatology services require integrated care along the whole patient pathway, across secondary, community and primary care. This is \ndue to\n \nthe \ndiag\nnostic\n \ninfrastructure required, and the complexity of autoimmune diseases which can affect multiple organ systems\n.\n \n&#xa0;\n8.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nWherever rheumatology services are delivered\n,\n there needs to be \nan \nextensive \ndiagnostics infrastructure in place incorporating MRI, ultrasound/X-ray and complex blood testing\n.\n \nUnless there is a major investment in community diagnostic centres, \nthis will continue to be provided in acute or community hospital settings.\n \nThe benefit of having these diagnostic tools in a ‘one-stop shop’ is that the patient avoids the inconve\nnience of multiple appointments \n(and\n associated multiple costs\n) and\n the crucial time period from symptom onset to treatment is minimised. \n&#xa0;\n9.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nEarly intervention is clinically significant in rheumatology. Up to three months after symptom onset, rheumatic diseases can be treated effectively (to a low level or remission) with relatively inexpensive disease-modifying antirheumatic drugs (DMARDS). A treatment delay of more than three months can result in a more aggressive course to the disease which \ncauses long term damage to joints, and\n require\ns\n expensive biologic treatments.\n&#xa0;\n10.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nAlthough the NICE guideline requires that\n patie\nnts are put onto DMARDs within three\n months of symptom onset\n, a \nNAO report in 2009 \nfound that this happens with only 10% of patients\n.\n This is in part due to delays in being seen by a rheumatologist and partly due to local differences in the access level to key drugs.\n The average delay in the UK in GP surgeries is around nine months, by which time joint damage in aggressive disease has already occurred.\n&#xa0;\n11.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nThe same report concluded that\n o\nnly 63% of patients in acute trusts provided annual review for Rheumatoid Arthritis patients to monitor disease progression a\nnd emergence of co-morbidities.\n This indicates that \nthere is some way to go in integrating care for ongoing management of patients with rheumatic disease, as well as initial diagnosis and treatment.\n&#xa0;\n12.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nThe significance of this is \nshown\n in a recent National Rheumatoid Arthritis Society\n (NRAS)\n recently report\n5\n that highlights the range and impact of comorbidities associated with rheumatoid arthritis, and demonstrates the extent to which rheumatology services \nneed to\n be linked to other specialist and community services in a coordinated and holistic manner. Key points from this report include the following:\n13.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nMost\n financial incentives for good practice in \nthe current system\n only focus on parts of the pathway – \ndiscreet\n pieces of care as opposed to the whole \npatient care package\n. \nThis approach is a key system barrier to the principle of integrated care.\nCommissioner support, and best practice examples14.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nThe BSR\n have joined\n with Arthritis Care and \nNRAS\n \nto \nform the Rheumatology Commissioning Support \nAlliance – a project funded by the \nDepartment of Health\n to \nsupport commissioners and develop tools to demonstrate how better services for patients and better value for the NHS can both result from a more service-user-centred approach.\n \n&#xa0;\n15.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nThe BSR has also recently launched a Commissioning Toolkit for Providers\n. This package aims to help rheumatology professionals develop their knowledge and skills to design effective services and make the most of commissioning opportunities.\n&#xa0;\n16.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nIn addition to the initiatives above, \nthe BSR is proactively developing a hub of good practice service models. We intend to publish case studies in the \nautumn\n, however in advance of this we outline two models\n below\n that give a flavour of current initia\ntives being delivered in the UK\n.\n&#xa0;\n17.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nSite A example\n :\n18.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nSite A outcome: reduced work loss due to depression and anxiety, and 40% reduction in the need to use expensive biologic drugs.&#xa0;\n19.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nSite B\n example:\n20.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nSite B outcome: Savings of over a quarter of a million pounds per year over the last three years. These are shared between the commissioner and provider.&#xa0;21.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nThe BSR is happy to\n expand further on any of the points raised in this submission.\nMay 2013\n BSR website: http://www.rheumatology.org.uk/\n Third Edition Long Term Conditions Compendium, Department of Health (May 2012): https://www.gov.uk/government/news/third-edition-of-long-term-conditions-compendium-published\n UK health performance: findings of the Global Burden of Disease study 2010: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60355-4/abstract\nNICE guideline for rheumatoid arthritis: http://publications.nice.org.uk/rheumatoid-arthritis-cg79\n NRAS ‘The Impact of Rheumatoid Arthritis Co-morbidities’ December 2012: http://www.nras.org.uk/includes/documents/cm_docs/2012/t/1_the_impact_of_rheumatoid_arthritis_comorbidities_final_pdf_pdf.pdf\n NAO rheumatoid arthritis report 2009: http://www.nao.org.uk/report/services-for-people-with-rheumatoid-arthritis/\n BSR Commissioning toolkit, March 2013: http://www.rheumatology.org.uk/about_bsr/press_releases/commissioning_toolkit_launched.aspx\n"